All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or Myeloma crowd.
During the 18th International Myeloma Workshop, the Multiple Myeloma Hub spoke with Hermann Einsele, Julius-Maximilians-Universität Würzburg, Würzburg, DE. He discussed the top five communications from the 18th International Myeloma Workshop (IMW).
My top 5 communications from the 18th IMW
Einsele discusses new advances, including the CARTITUDE-1 (NCT03548207) trial, and new immunotherapeutic strategies presented in the IMW.
Access and future prospects of advanced immunotherapies for multiple myeloma in Europe
During the 4th European CAR T-cell Meeting, the Multiple Myeloma Hub was pleased to speak with Michel Delforge, UZ Leuven, Leuven, BE. We asked, What are the...
Editorial theme | Neurotoxicity and anti-BCMA agents
Chimeric antigen receptor (CAR) T-cell therapy (CAR-T) and bispecific antibodies represent two novel immunotherapeutic treatment modalities in the relapsed/refractory (R/R) setting of multiple...
Subscribe to get the best content related to multiple myeloma delivered to your inbox